Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CARANYSE:CLDINASDAQ:GRCENASDAQ:SNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$5.38-2.7%$5.04$2.71▼$11.52$24.61M0.566,468 shs8,598 shsCLDICalidi Biotherapeutics$0.70+3.6%$0.94$0.58▼$8.30$18.40M1.06858,142 shs148,138 shsGRCEGrace Therapeutics$2.27-5.8%$3.05$2.07▼$4.97$23.02M1.1981,229 shs11,180 shsSNGXSoligenix$2.27-2.6%$2.35$1.83▼$14.92$5.70M2.03787,730 shs39,732 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics+2.58%+5.74%+10.38%+2.43%-36.89%CLDICalidi Biotherapeutics-3.51%-16.66%-30.88%-54.65%+67,119,900.00%GRCEGrace Therapeutics-5.86%-5.49%-21.24%-34.86%+240,999,900.00%SNGXSoligenix-1.69%0.00%-0.85%-19.38%-75.32%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARACara Therapeutics4.0091 of 5 stars3.03.00.04.23.80.80.6CLDICalidi Biotherapeutics1.6772 of 5 stars3.50.00.00.00.61.70.6GRCEGrace Therapeutics2.4736 of 5 stars3.50.00.00.02.70.81.3SNGXSoligenix1.3024 of 5 stars0.05.00.00.02.20.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics 2.00Hold$27.84417.47% UpsideCLDICalidi Biotherapeutics 3.00Buy$15.002,057.03% UpsideGRCEGrace Therapeutics 3.00Buy$12.00428.63% UpsideSNGXSoligenix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SNGX, CARA, GRCE, and CLDI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/18/2025GRCEGrace TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 3/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$7.14M3.45N/AN/A$12.58 per share0.43CLDICalidi Biotherapeutics$50K368.06N/AN/A($2.32) per share-0.30GRCEGrace TherapeuticsN/AN/AN/AN/A$5.14 per shareN/ASNGXSoligenix$840K6.78N/AN/A$3.83 per share0.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$21.01N/A∞N/A-1,099.76%-367.97%-107.43%5/12/2025 (Estimated)CLDICalidi Biotherapeutics-$29.22MN/A0.00N/AN/AN/AN/A-344.45%N/AGRCEGrace Therapeutics-$12.85M-$1.16N/AN/AN/AN/A-20.10%-17.10%N/ASNGXSoligenix-$6.14M-$6.11N/AN/AN/A-1,473.38%-223.29%-74.18%5/9/2025 (Estimated)Latest SNGX, CARA, GRCE, and CLDI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2025Full YearSNGXSoligenix-$0.95-$1.14-$0.19-$1.14$0.20 million$0.20 million2/13/2025Q3 2025GRCEGrace Therapeutics-$0.27-$0.26+$0.01-$0.36N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/ACLDICalidi BiotherapeuticsN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/ASNGXSoligenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.774.71CLDICalidi BiotherapeuticsN/A0.190.19GRCEGrace TherapeuticsN/A6.066.06SNGXSoligenixN/A2.282.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%CLDICalidi Biotherapeutics12.53%GRCEGrace Therapeutics6.08%SNGXSoligenix3.60%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics3.10%CLDICalidi Biotherapeutics24.28%GRCEGrace Therapeutics13.51%SNGXSoligenix2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics804.57 million4.43 millionOptionableCLDICalidi Biotherapeutics3826.46 million20.04 millionN/AGRCEGrace TherapeuticsN/A10.14 million8.77 millionN/ASNGXSoligenix202.51 million2.44 millionNot OptionableSNGX, CARA, GRCE, and CLDI HeadlinesRecent News About These CompaniesSoligenix Reports Publication Describing Preclinical Efficacy Of CiVax - Quick FactsMarch 27 at 7:27 PM | nasdaq.comSoligenix selects IBN to spearhead corporate communicationsMarch 26 at 12:53 PM | markets.businessinsider.comSNGX: Preclinical Data Shows CiVax™ Booster Induces Broad Protection Against COVID-19…March 26 at 12:53 PM | msn.comSoligenix Announces Publication Demonstrating CiVax Booster Induces Rapid Broad Protection Against COVID-19 VariantsMarch 26 at 2:51 AM | medindia.netIBN Initiates Coverage of Soligenix Inc.March 25 at 8:30 AM | globenewswire.comSoligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 VariantsMarch 25 at 7:30 AM | prnewswire.comSoligenix Trumps Year-End FinancialsMarch 21, 2025 | baystreet.caSoligenix Announces Recent Accomplishments and Year End 2024 Financial ResultsMarch 21, 2025 | prnewswire.comWhy Soligenix (NASDAQ: SNGX) Is ‘One to Watch’March 20, 2025 | theglobeandmail.comSoligenix (SNGX) to Release Earnings on FridayMarch 19, 2025 | americanbankingnews.comHyBryte™ Treatment Studies Presented at Two Medical Conferences in MarchMarch 6, 2025 | prnewswire.comSoligenix Aims To Push The Boundaries In Treating Rare DiseasesFebruary 26, 2025 | msn.comEQS-News: Soligenix Aims To Push The Boundaries In Treating Rare DiseasesFebruary 25, 2025 | markets.businessinsider.comSNGX: Presentation Highlights HyBryte Potential in CTCL…February 24, 2025 | msn.comEQS-News: Improving Patient Quality Of Life: Soligenix Progresses Treatment For Painful Ulcers Associated With Rare Behcet's DiseaseFebruary 21, 2025 | finanzen.atEQS-News: Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And 2026February 21, 2025 | markets.businessinsider.comSoligenix IncFebruary 18, 2025 | money.usnews.comSoligenix settles debt with Pontifax lendersFebruary 10, 2025 | msn.comSoligenix Repays Loan, Boosting Financial FlexibilityFebruary 10, 2025 | tipranks.comSoligenix on Way to Bio Conference in NYCFebruary 4, 2025 | baystreet.caNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyAST SpaceMobile Stock Surges 17% After Analyst UpgradeBy Nathan Reiff | February 26, 2025View AST SpaceMobile Stock Surges 17% After Analyst UpgradeVolatility Is Back: 3 Stocks To Cushion the S&P 500's SwingsBy Gabriel Osorio-Mazilli | February 27, 2025View Volatility Is Back: 3 Stocks To Cushion the S&P 500's SwingsCarMax and Carvana: Steering the Used Car MarketBy Jeffrey Neal Johnson | March 27, 2025View CarMax and Carvana: Steering the Used Car MarketSNGX, CARA, GRCE, and CLDI Company DescriptionsCara Therapeutics NASDAQ:CARA$5.38 -0.15 (-2.71%) Closing price 03:58 PM EasternExtended Trading$5.60 +0.22 (+4.09%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Calidi Biotherapeutics NYSE:CLDI$0.70 +0.02 (+3.61%) Closing price 04:00 PM EasternExtended Trading$0.68 -0.01 (-1.64%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.Grace Therapeutics NASDAQ:GRCE$2.27 -0.14 (-5.81%) As of 03:59 PM EasternGrace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.Soligenix NASDAQ:SNGX$2.27 -0.06 (-2.58%) Closing price 03:59 PM EasternExtended Trading$2.27 0.00 (0.00%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intuitive Machines Gains After Earnings Beat, NASA Missions Ahead Maybe It’s Time to Buy Some GameStop Stock Intel's Strategy to Win the Next AI Frontier Is Alphabet Too Cheap to Ignore After Its Recent Correction? Qualcomm Stock Is Coiling for a Breakout Tesla Stock: Has the Mother of All Comebacks Begun? Fortinet: A Top Cybersecurity Stock With Growth Catalysts Energy Transfer: Powering Data With Dividends and Diversification Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
